Type I interferon induces cancer stem cells-mediated chemotherapy resistance

In a recent study in Nature Immunology, Musella et al. demonstrate that suboptimal type I interferon (IFN-I) signaling in tumors undergoing immunogenic cell death (ICD) facilitates the accumulation of cancer stem cells (CSCs) by triggering the epigenetic regulator lysine demethylase 1B (KDM1B). KDM1...

Descripción completa

Detalles Bibliográficos
Autores principales: De Martino, Mara, Vanpouille-Box, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518997/
https://www.ncbi.nlm.nih.gov/pubmed/36185803
http://dx.doi.org/10.1080/2162402X.2022.2127274
_version_ 1784799307760664576
author De Martino, Mara
Vanpouille-Box, Claire
author_facet De Martino, Mara
Vanpouille-Box, Claire
author_sort De Martino, Mara
collection PubMed
description In a recent study in Nature Immunology, Musella et al. demonstrate that suboptimal type I interferon (IFN-I) signaling in tumors undergoing immunogenic cell death (ICD) facilitates the accumulation of cancer stem cells (CSCs) by triggering the epigenetic regulator lysine demethylase 1B (KDM1B). KDM1B stands out as a promising target for the development of novel strategies to improve anti-cancer responses driven by ICD.
format Online
Article
Text
id pubmed-9518997
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-95189972022-09-29 Type I interferon induces cancer stem cells-mediated chemotherapy resistance De Martino, Mara Vanpouille-Box, Claire Oncoimmunology Commentary In a recent study in Nature Immunology, Musella et al. demonstrate that suboptimal type I interferon (IFN-I) signaling in tumors undergoing immunogenic cell death (ICD) facilitates the accumulation of cancer stem cells (CSCs) by triggering the epigenetic regulator lysine demethylase 1B (KDM1B). KDM1B stands out as a promising target for the development of novel strategies to improve anti-cancer responses driven by ICD. Taylor & Francis 2022-09-22 /pmc/articles/PMC9518997/ /pubmed/36185803 http://dx.doi.org/10.1080/2162402X.2022.2127274 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
De Martino, Mara
Vanpouille-Box, Claire
Type I interferon induces cancer stem cells-mediated chemotherapy resistance
title Type I interferon induces cancer stem cells-mediated chemotherapy resistance
title_full Type I interferon induces cancer stem cells-mediated chemotherapy resistance
title_fullStr Type I interferon induces cancer stem cells-mediated chemotherapy resistance
title_full_unstemmed Type I interferon induces cancer stem cells-mediated chemotherapy resistance
title_short Type I interferon induces cancer stem cells-mediated chemotherapy resistance
title_sort type i interferon induces cancer stem cells-mediated chemotherapy resistance
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518997/
https://www.ncbi.nlm.nih.gov/pubmed/36185803
http://dx.doi.org/10.1080/2162402X.2022.2127274
work_keys_str_mv AT demartinomara typeiinterferoninducescancerstemcellsmediatedchemotherapyresistance
AT vanpouilleboxclaire typeiinterferoninducescancerstemcellsmediatedchemotherapyresistance

Ejemplares similares